Loading
A decoy protein can bind MYC's partner and block it. Delivering the instructions for that decoy as mRNA in a fat nanoparticle avoids having to inject the protein itself.
Omomyc, a dominant-negative MYC variant, shrinks tumours in mouse models and a purified-protein version (OMO-103) has completed a first-in-human study with signs of target engagement. Protein delivery is the limitation. Encoding Omomyc-like miniproteins in lipid-nanoparticle mRNA, as used for COVID vaccines and now for intratumoural cytokines, would allow repeated dosing and tumour-biased delivery.
Shares Orna Therapeutics (Eli Lilly), Moderna, Drugging the 'undruggable' cancer targets, Personalised neoantigen (mRNA) vaccines.
Shares Orna Therapeutics (Eli Lilly), Moderna, Personalised neoantigen (mRNA) vaccines.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, Small-cell lung cancer.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers, Pancreatic ductal adenocarcinoma.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.